Looking for information about Dupuytrens disease? Click here

This is Xiapex

Xiapex (collagenase clostridium histolyticum) is a minimally invasive local treatment which has been shown to significantly reduce the penile curvature deformity and the patient-reported bother in men with Peyronie’s disease.1,2

Read more

Become a registered doctor!

Xiapex must be administered by a physician appropriately trained in the correct administration of the product and experienced in the diagnosis and treatment of male urological diseases.

To Xiapex training

Questions and answers to physicians

Show all answers
Hide all answers
  • What is Xiapex?


    Xiapex is the first EMA approved medicine for patients with Peyronie’s disease as an alternative to surgery or surgical procedures. Xiapex is indicated for the treatment of adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.1

  • How does Xiapex work?

    The signs and symptoms of Peyronie’s disease are caused by a collagen plaque. Injection of Xiapex into a Peyronie’s plaque, which is comprised mostly of collagen, may result in enzymatic disruption of the plaque. Following this disruption of the plaque, penile curvature deformity and patient bother caused by Peyronie’s disease are reduced.

    Xiapex is a combination of two purified clostridial collagenases for injection that enzymatically disrupts the contracting cord and thus reduces the contraction.1

  • How is Xiapex dosed?


    The dose of Xiapex is 0,58 mg per injection administered into a Peyronie’s plaque. If more than one plaque is present, inject into the plaque causing the curvature deformity.

  • How is Xiapex stored?


    Prior to reconstitution, the vials of lyophilized powder of Xiapex and sterile diluent should be stored in a refrigerator at 2°C to 8°C. Do not freeze.

  • What are the most common side effects?


    Most adverse reactions were local events of the penis and groin and the majority of these events were of mild or moderate severity, and most (79%) resolved within 14 days of the injection. The adverse reaction profile was similar after each injection, regardless of the number of injections administered. The most frequently reported adverse drug reactions (>25%) during the Xiapex clinical studies (832 male patients, 551 patients received Xiapex) were penile haematoma, penile swelling and penile pain. Severe penile haematoma including severe injection site haematoma were reported with the frequency very common.1

  • Why is the Xiapex training program needed?


    The European Medicines Agency has required that Sobi shall ensure that all physicians who are expected to prescribe/use the product are appropriately trained in the correct administration of the product and experienced in the diagnosis and management of the disease. Sobi offers a comprehensive training program designed to ensure proficiency and to minimize any risks related to administration, such as corporal rupture.

Are you a healthcare professional?

Dupuytren’s disease

Peyronie’s disease